Article

T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1

2025-12-08

Abstract excerpt

<title>Abstract</title> <p>Bispecific antibodies are increasingly used in multiple myeloma (MM) treatment. Those targeting CD3 and CD28 mimic T cell activation's dual-signal system to boost anti-tumor response. CD38 is highly expressed on MM cells and PD-L1 is an immunosuppressive molecule related to poor prognosis in MM patients. This study aimed to explore bispecific antibody combinations' cytotoxic effects on...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 38ebe313-27c7-51cf-a72a-6deeee35c13a
DOI: 10.21203/rs.3.rs-8174877/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1DOI 10.21203/rs.3.rs-8174877/v1Read

Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signalling demonstrate efficacy and safety in preclinical models of Multiple MyelomaSemantic proximity Read

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple MyelomaSemantic proximity Read

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaSemantic proximity Read

Teclistamab: Mechanism of action, clinical, and translational scienceSemantic proximity Read

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myelomaSemantic proximity Read

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read

Principles and Current Clinical Landscape of Multispecific Antibodies against CancerSemantic proximity Read

Bispecific antibodies for immune cell retargeting against cancerSemantic proximity Read

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity Read